234 related articles for article (PubMed ID: 26418749)
1. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
Chen J; Futami K; Petillo D; Peng J; Wang P; Knol J; Li Y; Khoo SK; Huang D; Qian CN; Zhao P; Dykema K; Zhang R; Cao B; Yang XJ; Furge K; Williams BO; Teh BT
PLoS One; 2008; 3(10):e3581. PubMed ID: 18974783
[TBL] [Abstract][Full Text] [Related]
3. Disruption of tubular Flcn expression as a mouse model for renal tumor induction.
Chen J; Huang D; Rubera I; Futami K; Wang P; Zickert P; Khoo SK; Dykema K; Zhao P; Petillo D; Cao B; Zhang Z; Si S; Schoen SR; Yang XJ; Zhou M; Xiao GQ; Wu G; Nordenskjöld M; Tauc M; Williams BO; Furge KA; Teh BT
Kidney Int; 2015 Nov; 88(5):1057-69. PubMed ID: 26083655
[TBL] [Abstract][Full Text] [Related]
4. Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression.
Nagashima K; Fukushima H; Shimizu K; Yamada A; Hidaka M; Hasumi H; Ikebe T; Fukumoto S; Okabe K; Inuzuka H
Oncotarget; 2017 Feb; 8(6):9947-9960. PubMed ID: 28039480
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
Lu X; Wei W; Fenton J; Nahorski MS; Rabai E; Reiman A; Seabra L; Nagy Z; Latif F; Maher ER
Mol Cancer Ther; 2011 Jan; 10(1):80-9. PubMed ID: 21220493
[TBL] [Abstract][Full Text] [Related]
6. Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.
Hudon V; Sabourin S; Dydensborg AB; Kottis V; Ghazi A; Paquet M; Crosby K; Pomerleau V; Uetani N; Pause A
J Med Genet; 2010 Mar; 47(3):182-9. PubMed ID: 19843504
[TBL] [Abstract][Full Text] [Related]
7. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
Baba M; Furihata M; Hong SB; Tessarollo L; Haines DC; Southon E; Patel V; Igarashi P; Alvord WG; Leighty R; Yao M; Bernardo M; Ileva L; Choyke P; Warren MB; Zbar B; Linehan WM; Schmidt LS
J Natl Cancer Inst; 2008 Jan; 100(2):140-54. PubMed ID: 18182616
[TBL] [Abstract][Full Text] [Related]
8. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).
Lu X; Boora U; Seabra L; Rabai EM; Fenton J; Reiman A; Nagy Z; Maher ER
Oncogene; 2014 Feb; 33(8):956-65. PubMed ID: 23416984
[TBL] [Abstract][Full Text] [Related]
10. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
[No Abstract] [Full Text] [Related]
11. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic value of SC66 in human renal cell carcinoma cells.
Xu M; Wang Y; Zhou LN; Xu LJ; Jin ZC; Yang DR; Chen MB; Zhu J
Cell Death Dis; 2020 May; 11(5):353. PubMed ID: 32393791
[TBL] [Abstract][Full Text] [Related]
13. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
14. Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.
Sakamoto H; Yamasaki T; Sumiyoshi T; Takeda M; Shibasaki N; Utsunomiya N; Arakaki R; Akamatsu S; Kobayashi T; Inoue T; Kamba T; Nakamura E; Ogawa O
Cancer Med; 2021 Jan; 10(1):119-134. PubMed ID: 33107222
[TBL] [Abstract][Full Text] [Related]
15. Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma.
Ma Z; Liu W; Zeng J; Zhou J; Guo P; Xie H; Yang Z; Zheng L; Xu S; Wang X; Chang LS; He D; Li L
Oncol Rep; 2015 Nov; 34(5):2461-8. PubMed ID: 26323996
[TBL] [Abstract][Full Text] [Related]
16. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
17. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
18. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.
Hasumi Y; Baba M; Ajima R; Hasumi H; Valera VA; Klein ME; Haines DC; Merino MJ; Hong SB; Yamaguchi TP; Schmidt LS; Linehan WM
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18722-7. PubMed ID: 19850877
[TBL] [Abstract][Full Text] [Related]
19. Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.
Hasumi H; Baba M; Hasumi Y; Huang Y; Oh H; Hughes RM; Klein ME; Takikita S; Nagashima K; Schmidt LS; Linehan WM
J Natl Cancer Inst; 2012 Nov; 104(22):1750-64. PubMed ID: 23150719
[TBL] [Abstract][Full Text] [Related]
20. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
